Serendipity and the discovery of novel compounds that restore mitochondrial plasticity

Clin Pharmacol Ther. 2014 Dec;96(6):672-83. doi: 10.1038/clpt.2014.174. Epub 2014 Sep 4.

Abstract

The mitochondrial electron transport chain (ETC) plays a central role in energy generation in the cell. Mitochondrial dysfunctions diminish adenosine triphosphate (ATP) production and result in insufficient energy to maintain cell function. As energy output declines, the most energetic tissues are preferentially affected. To satisfy cellular energy demands, the mitochondrial ETC needs to be able to elevate its capacity to produce ATP at times of increased metabolic demand or decreased fuel supply. This mitochondrial plasticity is reduced in many age-associated diseases. In this review, we describe the serendipitous discovery of a novel class of compounds that selectively target cardiolipin on the inner mitochondrial membrane to optimize efficiency of the ETC and thereby restore cellular bioenergetics in aging and diverse disease models, without any effect on the normal healthy organism. The first of these compounds, SS-31, is currently in multiple clinical trials.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenosine Triphosphate / biosynthesis
  • Aging / metabolism
  • Burns / drug therapy
  • Burns / metabolism
  • Cardiolipins / physiology
  • Cytochromes c / metabolism
  • Drug Discovery*
  • Electron Transport
  • Energy Metabolism / drug effects
  • Heart Failure / drug therapy
  • Heart Failure / metabolism
  • Humans
  • Insulin Resistance
  • Mitochondria / drug effects*
  • Mitochondria / physiology
  • Myocardial Reperfusion Injury / drug therapy
  • Oligopeptides / pharmacology*
  • Oligopeptides / therapeutic use

Substances

  • Cardiolipins
  • Oligopeptides
  • arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide
  • Adenosine Triphosphate
  • Cytochromes c